ERYP vs. PLX, IKT, IZTC, JATT, CRTX, ZIVO, ALVR, FNCH, SRNE, and NKGN
Should you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), JATT Acquisition (JATT), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), AlloVir (ALVR), Finch Therapeutics Group (FNCH), Sorrento Therapeutics (SRNE), and NKGen Biotech (NKGN). These companies are all part of the "medical" sector.
ERYTECH Pharma vs. Its Competitors
ERYTECH Pharma (NASDAQ:ERYP) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.
Protalix BioTherapeutics has higher revenue and earnings than ERYTECH Pharma.
ERYTECH Pharma has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. ERYTECH Pharma's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.
ERYTECH Pharma has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.13, suggesting that its share price is 113% less volatile than the S&P 500.
In the previous week, Protalix BioTherapeutics had 9 more articles in the media than ERYTECH Pharma. MarketBeat recorded 9 mentions for Protalix BioTherapeutics and 0 mentions for ERYTECH Pharma. ERYTECH Pharma's average media sentiment score of 0.00 beat Protalix BioTherapeutics' score of -0.25 indicating that ERYTECH Pharma is being referred to more favorably in the media.
1.1% of ERYTECH Pharma shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 1.9% of ERYTECH Pharma shares are owned by insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Protalix BioTherapeutics has a consensus target price of $15.00, suggesting a potential upside of 600.93%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than ERYTECH Pharma.
Summary
Protalix BioTherapeutics beats ERYTECH Pharma on 8 of the 14 factors compared between the two stocks.
Get ERYTECH Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ERYP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ERYTECH Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:ERYP) was last updated on 10/22/2025 by MarketBeat.com Staff
